Trial Profile
A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Nangibotide (Primary)
- Indications Septic shock
- Focus Adverse reactions; First in man
- Sponsors Inotrem
- 08 Jun 2018 Results published in the British Journal of Clinical Pharmacology
- 15 Nov 2017 According to an Inotrem media release, based on the data of this trial, European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for MOTREMTM in the field of septic shock.
- 26 Sep 2016 New trial record